Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.

X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of ...

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...

Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential Clinical Pipeli ...

HealthDay News — Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative aspiration pneumonia, according to a study published online March ...

Dow Jones and other indexes rallied in the stock market on Monday amid news that Trump's tariffs may not target some sectors.

Lyndra Therapeutics, a drug developer that spun out of the lab of MIT professor Bob Langer in 2015, is winding down ...

Akebia-supported posters will be displayed at NKF SCM25 during Exhibit Hall hours. NKF SCM25 attendees can also visit Akebia ...

The Utah Jazz are back to the grind on Tuesday night, facing off against the Memphis Grizzlies for their fifth of a six-game ...

Uncertainty about the scope of Trump's upcoming tariffs has investors treading carefully. Stocks soared on Monday amid signs ...

Cirius Therapeutics, Inc., developing innovative therapies for patients suffering with diseases caused by insulin resistance, including obesity/overweight and type 2 diabetes (T2D), today announced ...